Koen P Rovers1, Geert A Simkens1, Cornelis J Punt2, Susan van Dieren3, Pieter J Tanis3, Ignace H de Hingh4. 1. Department of Surgical Oncology, Catharina Hospital, Eindhoven, The Netherlands. 2. Department of Medical Oncology, Academic Medical Centre, Amsterdam, The Netherlands. 3. Department of Surgical Oncology, Academic Medical Centre, Amsterdam, The Netherlands. 4. Department of Surgical Oncology, Catharina Hospital, Eindhoven, The Netherlands. Electronic address: ignace.d.hingh@catharinaziekenhuis.nl.
Abstract
BACKGROUND/ PURPOSE: Despite its widespread use, no randomised studies have investigated the value of perioperative systemic therapy as adjunct to cytoreduction and HIPEC for colorectal peritoneal metastases. This systematic review evaluated the available evidence, which consists of non-randomised studies only. METHODS: A systematic search identified studies that investigated the influence of neoadjuvant, adjuvant, or perioperative systemic therapy on overall survival (OS). RESULTS: The 11 included studies (n=1708) were clinically heterogeneous and subject to selection bias. Studies on neoadjuvant systemic therapy revealed OS benefit (n=3), no OS benefit (n=1), and superiority of chemotherapy with bevacizumab vs. chemotherapy (n=2). Studies on adjuvant systemic therapy showed no OS benefit (n=3). Studies on perioperative systemic therapy demonstrated OS benefit (n=1), and superiority of modern vs. conventional systemic therapy(n=1). CONCLUSION: Significant limitations of available evidence question the widespread use of perioperative systemic therapy in this setting, stress the need for randomised studies, and impede conclusions regarding optimal timing and regimens. Included studies may suggest a survival benefit of neoadjuvant systemic therapy.
BACKGROUND/ PURPOSE: Despite its widespread use, no randomised studies have investigated the value of perioperative systemic therapy as adjunct to cytoreduction and HIPEC for colorectal peritoneal metastases. This systematic review evaluated the available evidence, which consists of non-randomised studies only. METHODS: A systematic search identified studies that investigated the influence of neoadjuvant, adjuvant, or perioperative systemic therapy on overall survival (OS). RESULTS: The 11 included studies (n=1708) were clinically heterogeneous and subject to selection bias. Studies on neoadjuvant systemic therapy revealed OS benefit (n=3), no OS benefit (n=1), and superiority of chemotherapy with bevacizumab vs. chemotherapy (n=2). Studies on adjuvant systemic therapy showed no OS benefit (n=3). Studies on perioperative systemic therapy demonstrated OS benefit (n=1), and superiority of modern vs. conventional systemic therapy(n=1). CONCLUSION: Significant limitations of available evidence question the widespread use of perioperative systemic therapy in this setting, stress the need for randomised studies, and impede conclusions regarding optimal timing and regimens. Included studies may suggest a survival benefit of neoadjuvant systemic therapy.
Authors: Marco Tonello; Dario Baratti; Paolo Sammartino; Andrea Di Giorgio; Manuela Robella; Cinzia Sassaroli; Massimo Framarini; Mario Valle; Antonio Macrì; Luigina Graziosi; Federico Coccolini; Piero Vincenzo Lippolis; Roberta Gelmini; Marcello Deraco; Daniele Biacchi; Francesco Santullo; Marco Vaira; Katia Di Lauro; Fabrizio D'Acapito; Fabio Carboni; Giuseppe Giuffrè; Annibale Donini; Paola Fugazzola; Pinuccia Faviana; Lorena Sorrentino; Antonio Scapinello; Paola Del Bianco; Antonio Sommariva Journal: Ann Surg Oncol Date: 2021-11-16 Impact factor: 5.344
Authors: Koen P Rovers; Checca Bakkers; Felice N van Erning; Jacobus W A Burger; Simon W Nienhuijs; Geert A A M Simkens; Geert-Jan M Creemers; Patrick H J Hemmer; Cornelis J A Punt; Valery E P P Lemmens; Pieter J Tanis; Ignace H J T de Hingh Journal: JAMA Oncol Date: 2020-08-13 Impact factor: 31.777
Authors: Koen P Rovers; Checca Bakkers; Geert A A M Simkens; Jacobus W A Burger; Simon W Nienhuijs; Geert-Jan M Creemers; Anna M J Thijs; Alexandra R M Brandt-Kerkhof; Eva V E Madsen; Ninos Ayez; Nadine L de Boer; Esther van Meerten; Jurriaan B Tuynman; Miranda Kusters; Nina R Sluiter; Henk M W Verheul; Hans J van der Vliet; Marinus J Wiezer; Djamila Boerma; Emma C E Wassenaar; Maartje Los; Cornelis B Hunting; Arend G J Aalbers; Niels F M Kok; Koert F D Kuhlmann; Henk Boot; Myriam Chalabi; Schelto Kruijff; Lukas B Been; Robert J van Ginkel; Derk Jan A de Groot; Rudolf S N Fehrmann; Johannes H W de Wilt; Andreas J A Bremers; Philip R de Reuver; Sandra A Radema; Karin H Herbschleb; Wilhelmina M U van Grevenstein; Arjen J Witkamp; Miriam Koopman; Nadia Haj Mohammad; Eino B van Duyn; Walter J B Mastboom; Leonie J M Mekenkamp; Joost Nederend; Max J Lahaye; Petur Snaebjornsson; Cornelis Verhoef; Hanneke W M van Laarhoven; Aeilko H Zwinderman; Jeanette M Bouma; Onno Kranenburg; Iris van 't Erve; Remond J A Fijneman; Marcel G W Dijkgraaf; Patrick H J Hemmer; Cornelis J A Punt; Pieter J Tanis; Ignace H J T de Hingh Journal: BMC Cancer Date: 2019-04-25 Impact factor: 4.430
Authors: Michelle V Dietz; Job P van Kooten; Ibrahim Said; Alexandra R M Brandt-Kerkhof; Cornelis Verhoef; Andreas J A Bremers; Johannes H W de Wilt; Philip R de Reuver; Eva V E Madsen Journal: Ann Surg Oncol Date: 2022-05-05 Impact factor: 4.339
Authors: Michael P Flood; Joseph C H Kong; Kasmira Wilson; Helen Mohan; Peadar S Waters; Jacob J McCormick; Satish K Warrier; Jeanne Tie; Robert Ramsay; Michael Michael; Alexander G Heriot Journal: Ann Surg Oncol Date: 2022-04-09 Impact factor: 4.339